Get Premium to unlock powerful stock data
OSTO:SOBI (Sweden)  
Swedish Orphan Biovitrum AB logo

Swedish Orphan Biovitrum AB

kr 222.00 (+0.36%) Jul 1
On watch
P/E:
26.12
P/B:
2.76
Market Cap:
kr 65.52B ($ 6.36B)
Enterprise V:
kr 74.23B ($ 7.20B)
Volume:
217.62K
Avg Vol (2M):
884.32K
Also Trade In:
Volume:
217.62K
Market Cap kr:
65.52B
Market Cap $:
6.36B
PE Ratio:
26.12
Avg Vol (2-Month):
884.32K
Enterprise Value kr:
74.23B
Enterprise Value $:
7.20B
PB Ratio:
2.76
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website Sources Stock Report
Dataset
Financial Download Tutorials

Business Description

Description
Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum also acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched its hemophilia products Alprolix and Eloctate in Europe in 2016. In 2019, Sobi acquired rights to rare disease drug Gamifant, U.S. rights to Astra's RSV prevention drug Synagis, and rights to thrombocytopenia drug Doptelet (with the Dova acquisition). In 2020, new collaborations brought rights to gout drug pegadricase and complement-mediated disease drug Aspaveli.

Financials (Next Earnings Date:2022-07-19)

OSTO:SOBI's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil kr) 16,793
EPS (TTM) (kr) 8.5
Beta 0.98
Volatility % 38.93
14-Day RSI 58.37
14-Day ATR (kr) 6.910611
20-Day SMA (kr) 216.425
12-1 Month Momentum % 36.61
52-Week Range (kr) 154.1 - 245.4
Shares Outstanding (Mil) 295.16

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 7
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Swedish Orphan Biovitrum AB Filings

Document Form Filing Date
No Filing Data